Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.25 - Epicutaneous responses to Bradykinin Receptor 1 and 2 agonists, Histamine, and mast cell agonists in Angiotensin Converting Enzyme Inhibitor angioedema
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.18 - Evaluating the Penicillin Allergy Diagnosis Process with Real-Life Data
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.26 - Applying a phenotype-driven diagnostic algorithm to suspected hypersensitivity reactions to biologicals: a real-world experience
D2.27 - “Chronic Urticaria Following Dental Filling Procedure: A Clinical Evaluation”
D2.28 - When Cross-Reactivity Is Not the Answer: Immediate Multiple Drug Hypersensitivity to Aminopenicillins and Ceftriaxone
D2.29 - Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area
D2.541 - Healthy and unhealthy plant-based dietary patterns and asthma: a systematic review using validated dietary indices
D2.542 - Prevalance and risk factors of atopic dermatitis among preschool children Gaziantep, a province in South-Eastern Turkey
D2.540 - Nationwide Analysis of Domestic Mites in Germany
D2.543 - Clinical and Epidemiological Characteristics of Workers with Inflammatory Bowel Disease: A Cross-Sectional Study
D2.544 - Validation of the Turkish Version of the Mastocytosis Control Test
D3.232 - The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs
D3.231 - Gut Microbiome Dysbiosis in Antihistamine-Refractory Chronic Spontaneous Urticaria and Its Association with Disease Characteristics- A Cross-Sectional Case–Control Analysis
D3.233 - Polypharmacy-Associated Lichenoid Eruption Simulating Keratosis Lichenoides Chronica
D3.234 - Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure
D3.235 - Trends in Sensitization to Preservatives and Epoxy Resins among occupationally exposed workers: A 31-Year Patch Test analysis from Tunisia
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download